menu search

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Third fda advisor resigns after biogen's alzheimer's drug approval

A third FDA advisor has resigned following last week's controversial accelerated approval of Biogen's alzheime...

November 19, 2022, 7:43 am

Eli lilly ceo david ricks on positive alzheimer's drug trial data

Eli Lilly said on Monday a trial of its experimental alzheimer's drug donanemab showed it slowed by abo...

November 19, 2022, 7:10 am

This analyst breaks down the bull case for biogen's alzheimer's drug

CNBC's Kelly Evans and Bertha Coombs discuss Biogen's new alzheimer's drug and the battle for medicare ...

November 19, 2022, 4:37 am

Cramer: there will be push back on biogen's alzheimer's drug price

The Food and Drug Administration on Monday approved Biogen's alzheimer's disease drug aducanumab, makin...

November 19, 2022, 4:08 am

Eli lilly's alzheimer's drug gets fda breakthrough designation

CNBC's Meg Tirrell reports on how Eli Lilly's will seek FDA approval this year for its alzheimer's drug...

November 19, 2022, 2:34 am

Fda approves biogen alzheimer's treatment

CNBC's Meg Tirrell reports on FDA approval of Biogen's alzheimer's treatment under an 'accelerated appr...

November 19, 2022, 2:21 am

Fda's historic approval of biogen's alzheimer's drug

CNBC's Meg Tirrell on the FDA approval of Biogen's new alzheimer's drug. With CNBC's Brian Sullivan and...

November 19, 2022, 2:12 am

Cassava sciences announces $50 million registered direct offering of common stock

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stag...

November 18, 2022, 6:30 pm

Roche alzheimer's failure good news for rivals, analysts suggest

Analysts were busy chopping back forecasts for Swiss group Roche going forward after what was described by one as the 'unequivocal failure' of gantene...

November 15, 2022, 7:51 am

Cassava sciences stock pops after rival experiences setback in alzheimer's research

Yahoo Finance anchors Rachelle Akuffo, Seana Smith and Dave Briggs shares of Cassava moving higher on news that its rival Roche suffered a setback in ...

November 14, 2022, 4:40 pm

Eli lilly stock starts on front foot after rival alzheimer trial fails

Eli Lilly and Co (NYSE:LLY) stock was moving higher as Roche revealed that an experimental rival treatment for ...

November 14, 2022, 10:09 am

Eli lilly stock starts fresh week on front foot after rival alzheimer trial fails

Eli Lilly and Co (NYSE:LLY) stock was moving higher as Roche revealed that an experimental rival treatment for ...

November 14, 2022, 10:03 am

What's going on with biogen stock today? - biogen (nasdaq:biib)

Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's alzheimer's candid...

November 14, 2022, 9:48 am

Roche's alzheimer's drug fails in phase 3; here's the fallout for biogen, lilly, prothena and others

Roche said its experimental alzheimer's treatment failed in two final-phase studies, leading Biogen sto...

November 14, 2022, 9:17 am

Biogen shares jump 4.7% premarket on hopes for its alzheimer's treatment lecanemab

Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for ...

November 14, 2022, 6:41 am

Morphosys shares plunge after partner roche says alzheimer's drug trials didn't meet goals

German-listed shares of MorphoSys MOR, -31.96% MOR, +2.44% lost a third of their value on Monday after its partner Roche said an ...

November 14, 2022, 5:22 am

Roche says phase 3 studies for alzheimer's drug failed to meet primary endpoints

Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early alzheimer...

November 14, 2022, 2:13 am

Roche's alzheimer's drug fails to meet goal in long awaited trial

Roche said its alzheimer's drug candidate could not clearly be shown to slow dementia progression in tw...

November 14, 2022, 1:13 am


Search within

Pages Search Results: